Malignant pleural or peritoneal mesothelioma is invariably fatal cancer with options that are largely supportive in nature. The current first-line chemotherapy regimens including pemetrexed with or without cisplatin or carboplatin do not provide long-term survival. This cancer is highly angiogenic and thus preclinical and early data supported the use of anti-angiogenic agent thalidomide.
However, a recent clinical trial published in this month's issue of the journal Lancet Oncology shows that thalidomide when added to chemotherapy does not provide any additional benefit.
Oncology targets, strategies, cancer drug development and personalized medicine
Showing posts with label thalidomide. Show all posts
Showing posts with label thalidomide. Show all posts
Sunday, May 19, 2013
Wednesday, October 13, 2010
Old Drugs have a lot more Firepower
Celgene Corporation (NASDAQ:CELG) was in the news a few months ago for buying Abraxis BioScience for 2.9 billion (read: A Billionaire’s Biotech Deal And Old Drugs Reborn at forbes.com, or Prominent Drug Chief to Sell Abraxis BioScience to Celgene for $2.9 Billion at nytimes.com) With this purchase, Celgene has become a big player in the Oncology biz-space with two re-incarnated drugs:
Subscribe to:
Posts (Atom)